Real World Overall Survival of Patients With Metastatic Renal Cell Carcinoma Treated With Only Available Sunitinib and Pazopanib in First-Line Setting

Real World Overall Survival of Patients With Metastatic Renal Cell Carcinoma Treated With Only Available Sunitinib and Pazopanib in First-Line Setting

BackgroundThe emerging new standard of care for metastatic clear cell renal carcinoma (mRCC) becomes a challenge when access to new drugs is limited. In Serbia, sunitinib and pazopanib are the only available first-line therapies. The second-line treatment for mRCC has never been and is still not ava...

Full description

Bibliographic Details
Main Authors: Predrag Nikic, Nada Babovic, Zoran Dzamic, Svetlana Salma, Vesna Stojanovic, Suzana Matkovic, Zoran Pejcic, Kristina Juskic, Ivan Soldatovic
Format: Article
Language:English
Published: Frontiers Media S.A. 2022-06-01
Series:Frontiers in Oncology
Subjects:
metastatic clear cell renal carcinoma (mRCC)
overall survival (OS)
sunitinib
pazopanib
limited access to cancer therapy
real world data
Online Access:https://www.frontiersin.org/articles/10.3389/fonc.2022.892156/full

Internet

https://www.frontiersin.org/articles/10.3389/fonc.2022.892156/full

Similar Items